Objectives: An enhanced understanding of eosinophilic granulomatosis with polyangiitis (EGPA) in clinical practice may help identify areas where patient management could be improved.The objectives of this study were to examine the real-world demographics, patient diagnostic journey, disease burden, treatment patterns, and health-related quality of life (HRQoL) of patients with EGPA.Methods: Data were drawn from the Adelphi Real World EGPA Disease Specific Programme, a cross-sectional survey of patients with EGPA and their physicians in Europe (France, Germany, Italy, Spain, and the UK) and the USA from July to December 2023.Results: The study included 121 physicians and 503 patients.Most patients were White (89%), the mean (SD) age was 49.5 (15.3) years, and the distribution of sexes was balanced.Mean (SD) time between sign/symptom onset and EGPA diagnosis was 9.8 (19.1) months.Patients had a mean (SD) of 5.5 (3.8) signs and/or symptoms at diagnosis, and physician-perceived severity of EGPA was mild in 20%, moderate in 55%, and severe in 24% of patients.Glucocorticoids were the most prescribed therapies (79%), and the use of interleukin-5-/receptor alpha-targeted therapies was low (21% mepolizumab, 7% benralizumab, <1% reslizumab).Patient-reported HRQoL and work productivity were most impacted in those with organ damage, oral glucocorticoid dose 10 mg/day, blood eosinophil count 300 cells/L, or relapse, refractory, deteriorating, moderate, or severe disease.Conclusions: EGPA is associated with a considerable disease burden.Increased disease awareness to facilitate prompt diagnosis and treatment and optimised management to achieve remission and enhance patients' HRQoL are needed.
Spiera et al. (Wed,) studied this question.